Resmed (RMD) Shares Outstanding (Weighted Average) (2009 - 2026)

Resmed has reported Shares Outstanding (Weighted Average) for 18 years, with the latest figure at $145.3 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) fell 0.94% year-over-year to $145.3 million; the trailing twelve-month figure through Mar 2026 stood at $145.3 million (down 0.94% YoY), and the FY2025 full-year result was $146.7 million, changed 0.21% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $145.3 million, roughly flat from $145.8 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $147.1 million in Q4 2023, with the low at $145.3 million in Q1 2026.
• Historically, Shares Outstanding (Weighted Average) has averaged $146.6 million across 5 years, with a median of $146.7 million in 2025.
• Annual changes were most pronounced in 2023 — Shares Outstanding (Weighted Average) climbed 0.65% — and 2026, when it slipped 0.94%.
• Resmed's Shares Outstanding (Weighted Average) stood at $146.6 million in 2022, then advanced by 0.37% to $147.1 million in 2023, then decreased by 0.18% to $146.8 million in 2024, then decreased by 0.68% to $145.8 million in 2025, then declined by 0.34% to $145.3 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $145.3 million (Q1 2026), $145.8 million (Q4 2025), and $146.2 million (Q3 2025), per Business Quant data.